MISSIONPHARMA A/S: Financial statements 2017
CVR: 26902398
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
MISSIONPHARMA A/S (CVR 26902398) has filed annual accounts for 2017. In 2017, the company reported revenue of DKK 703,475,000 and a net result of DKK 76,150,000 compared with DKK 78,005,000 the year before. That is a decrease of 7.8% compared with the year before. The profit margin was 10.8%. Equity in the 2017 report amounted to DKK 284,014,000. The solvency ratio was 64.8%. The company had 60 employees in the financial year.
- Revenue
- DKK 703,475,000
- Gross Profit
- DKK 137,089,000
- Profit/Loss
- DKK 76,150,000
- Equity
- DKK 284,014,000
- Total Assets
- DKK 438,511,000
- Employees
- 60
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 703.5 mio. | 137.1 mio. | 76.2 mio. | 284 mio. | 60 |
| 2016 | 762.7 mio. | 142.6 mio. | 78 mio. | 209 mio. | 57 |
| 2015 | 753.9 mio. | 122.8 mio. | 73.8 mio. | 185.5 mio. | 49 |
| 2014 | 703.8 mio. | 129.5 mio. | 69 mio. | 162.3 mio. | 42 |
| 2013 | 537.9 mio. | 106.1 mio. | 44.1 mio. | 124.4 mio. | 45 |
Official annual report
Keep an eye on MISSIONPHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
MISSIONPHARMA A/S has published its annual report for 2016. Revenue came to DKK 762,676,000, and the net result was DKK 78,005,000.
About MISSIONPHARMA A/S
MISSIONPHARMA A/S is a Danish company of the type Aktieselskab based in Lynge, founded in 2002. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jean-Marc Pierre René Leccia and Edouard Marc Marie Favreau. The board consists of Eric Pierre Jean Muris (chair), Kim Erik Ginnerup, Ilona Maureen Fischer and Jean-Marc Pierre René Leccia. The company is owned by CFAO HEALTHCARE SA. The company has 67 employees (2026). In 2026, the company reported revenue of DKK 934,465,000 and a net result of DKK 120,205,000 compared with DKK 73,402,000 the year before. Equity in the 2026 report amounted to DKK 317,751,000.